基本分析
透過季節調整季營收，判斷美股整體趨勢，但注意股價有時候領先基本面的數據，應搭配其他領先指標判斷。
基本資料
個股的基本資料，以及所屬的類股和產業。
公司介紹
業務介紹
格勞科斯公司是一家從事眼科醫療技術和製藥的公司,專注於開發治療青光眼、角膜疾病和視網膜疾病的創新療法。該公司提供 iStent、iStent inject 和 iStent inject W 微型旁路支架,可在白內障手術中植入以增強房水流出,用於治療輕度至中度開角型青光眼。該公司的產品管線包括 iStent Infinite(一種設計用於單獨手術的三支架產品,適用於難治性青光眼患者)以及 iDose TR(一種基於微型設備平台的定向注射植入物,旨在提供治療性藥物劑量)。該公司通過直銷組織以及在美國和國際市場的分銷商銷售其產品。格勞科斯公司成立於1998年,總部位於加利福尼亞州聖克萊門特。
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.
警語
1. 資料僅供參考，不做任何獲利保證及特定股票與點位推薦建議。
2. 資料並不完整，需要完整資料請至相關網站索取。
3. 任何股市數據分析皆存在倖存者偏差。
